Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Inflammatory Bowel Disease, Ulcerative Colitis
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after…
- Trial name
- NCT00408174
- Testing
- Balsalazide disodium
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
- Trial name
- SEA TURTLE (NCT04577794)
- Testing
- GLPG3970
- Where
- 15 sites in Georgia, Moldova and 2 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Ulcerative Colitis
A Study of Pentasa in Patients With Ulcerative Colitis
Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).
- Trial name
- NCT01104753
- Where
- 30 sites in Czechia
- Volunteers
- 338 people
- Sponsor
- Ferring Pharmaceuticals
Active Ulcerative Colitis
Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled phase II study.
- Trial name
- NCT03235752
- Testing
- TJ301 300mg, TJ301 600mg
- Where
- 27 sites in China, South Korea and 1 more
- Volunteers
- 91 people
- Sponsor
- I-Mab Biopharma HongKong Limited
Ulcerative Colitis
A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC)
This study is only for the first in human phase 1a study designed to investigate the safety and tolerability of LIV001 in healthy participants.
- Trial name
- NCT05975047
- Testing
- LIV001
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Liveome Inc.
Crohn's Disease, Ulcerative Colitis
An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen
This is a study of the electronical dosing tool MedicPen and it's qualities with regards to user friendliness and medication compliance.
- Trial name
- NCT00917514
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Medicpen AB
Ulcerative Colitis, Crohn's Disease
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
- Trial name
- NCT01290042
- Testing
- AMG 181
- Where
- 8 sites in United States, Australia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Amgen
Colitis, Ulcerative
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT01959282
- Testing
- JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily
- Where
- 97 sites in United States, Australia and 12 more
- Volunteers
- 219 people
- Sponsor
- Janssen Research & Development, LLC
UC
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis: A Preliminary Exploration of 12-Week…
- Trial name
- NCT07435779
- Testing
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Ulcerative Colitis
A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis
The purpose of this study is to determine whether a treatment of a novel leukapheresis column is safe and effective in patients with moderate to severe ulcerative colitis.
- Trial name
- NCT01097590
- Testing
- Active TLA Gut™ column
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- IBD Column Therapies International AB
Ulcerative Colitis
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity…
- Trial name
- NCT00801723
- Testing
- Budesonide MMX 6 mg Tablet
- Where
- 58 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis
The purpose of this study is to investigate whether a novel dosage form of a prednisolone ester, called COLAL-PRED®, is useful in the treatment of ulcerative colitis.
- Trial name
- NCT00299013
- Testing
- COLAL-PRED®, Prednisolone
- Where
- 86 sites in Australia, Belgium and 13 more
- Volunteers
- 796 people
- Sponsor
- Alizyme
Ulcerative Colitis
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- TOPAZ-UC (NCT07186101)
- Testing
- LY4268989, Mirikizumab
- Where
- 147 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Diseases
IBDoc® Canadian User Performance Evaluation
The objective of the IBDoc® user performance evaluation is to demonstrate the ease-of-use of the IBDoc® calprotectin home test to allow patients with inflammatory bowel disease (IBD) to independently and correctly determine…
- Trial name
- NCT03408249
- Testing
- IBDoc calprotectin test, questionnaire
- Where
- 3 sites in Canada
- Volunteers
- 61 people
- Sponsor
- Bühlmann Laboratories AG
Ulcerative Colitis (UC)
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
- Trial name
- LEGACY (NCT01848561)
- Where
- 512 sites in United States, Australia and 19 more
- Volunteers
- 8,250 people
- Sponsor
- AbbVie
Ulcerative Colitis
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
- Trial name
- NCT00355901
- Testing
- Visilizumab (Nuvion®; HuM291)
- Where
- 40 sites in United States, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- PDL BioPharma, Inc.
Ulcerative Colitis
Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a…
- Trial name
- NCT00209287
- Testing
- Observe patients with inactive ulcerative colitis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Ferring Pharmaceuticals
Colitis, Ulcerative
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
This is a Phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability, efficacy and dose-response of GSK2831781 in participants with moderate to severe active…
- Trial name
- NCT03893565
- Testing
- GSK2831781 - Double Blind Phase, GSK2831781 - Open Label phase
- Where
- 61 sites in United States, Bulgaria and 13 more
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis
Objectives: The primary objective of this trial was to evaluate the patients response rate at the end of the study. Patients were considered responder if one of the following conditions occurs: Disease remission (Powell Tuck ≤ 3…
- Trial name
- Crocodex (NCT01171807)
- Testing
- Dex 21-P
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Quince Therapeutics S.p.A.
IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome)
Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.
This study will evaluate how well the a new stool test can distinguish inflammatory bowel disease (IBD) from non-IBD conditions compared with standard calprotectin testing and colonoscopy findings.
- Conditions
- IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome), Gastrointestinal Symptoms
- Trial name
- COMBI (NCT07471490)
- Where
- 2 sites in United States, Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- DiaSorin Inc.